JP2023513797A5 - - Google Patents
Info
- Publication number
- JP2023513797A5 JP2023513797A5 JP2022549152A JP2022549152A JP2023513797A5 JP 2023513797 A5 JP2023513797 A5 JP 2023513797A5 JP 2022549152 A JP2022549152 A JP 2022549152A JP 2022549152 A JP2022549152 A JP 2022549152A JP 2023513797 A5 JP2023513797 A5 JP 2023513797A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- pharmaceutical composition
- composition according
- inhibitor
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062977041P | 2020-02-14 | 2020-02-14 | |
| US62/977,041 | 2020-02-14 | ||
| PCT/US2021/018044 WO2021163633A1 (en) | 2020-02-14 | 2021-02-12 | Mono and combination therapies with ulk1/2 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023513797A JP2023513797A (ja) | 2023-04-03 |
| JP2023513797A5 true JP2023513797A5 (enExample) | 2024-02-20 |
Family
ID=77292775
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022549152A Pending JP2023513797A (ja) | 2020-02-14 | 2021-02-12 | Ｕｌｋ１／２阻害剤による単剤療法および併用療法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230130766A1 (enExample) |
| EP (1) | EP4103186A4 (enExample) |
| JP (1) | JP2023513797A (enExample) |
| KR (1) | KR20220154094A (enExample) |
| CN (1) | CN115484956A (enExample) |
| AU (1) | AU2021218740A1 (enExample) |
| WO (1) | WO2021163633A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115515588A (zh) | 2020-02-14 | 2022-12-23 | 萨克生物研究学院 | 大环ulk1/2抑制剂 |
| WO2022072668A1 (en) * | 2020-09-30 | 2022-04-07 | Salk Institute For Biological Studies | Patient selection biomarkers for treatment with ulk inhibitors |
| WO2024140401A1 (zh) * | 2022-12-30 | 2024-07-04 | 捷思英达控股有限公司 | 作为激酶抑制剂的杂环化合物以及包括其的组合物 |
| WO2025045182A1 (zh) * | 2023-09-01 | 2025-03-06 | 深圳众格生物科技有限公司 | Ulk1抑制剂及其制备方法和用途 |
| WO2025166124A1 (en) * | 2024-02-02 | 2025-08-07 | Deciphera Pharmaceuticals, Llc | Ulk inhibitors and methods of use thereof |
| WO2025166161A1 (en) * | 2024-02-02 | 2025-08-07 | Deciphera Pharmaceuticals, Llc | Ulk inhibitors and methods of use thereof |
| WO2025166180A1 (en) * | 2024-02-02 | 2025-08-07 | Deciphera Pharmaceuticals, Llc | Ulk inhibitors and methods of use thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005111016A1 (en) * | 2004-05-14 | 2005-11-24 | Pfizer Products Inc. | Pyrimidine derivatives for the treatment of abnormal cell growth |
| EP1794135A1 (en) * | 2004-09-27 | 2007-06-13 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
| ES2914099T3 (es) * | 2014-08-25 | 2022-06-07 | Salk Inst For Biological Studi | Inhibidores novedosos de ULK1 y métodos de uso de los mismos |
| AU2015317741B2 (en) * | 2014-09-17 | 2020-01-16 | Bristol-Myers Squibb Company | MK2 inhibitors and uses thereof |
-
2021
- 2021-02-12 AU AU2021218740A patent/AU2021218740A1/en active Pending
- 2021-02-12 KR KR1020227028939A patent/KR20220154094A/ko active Pending
- 2021-02-12 CN CN202180027793.4A patent/CN115484956A/zh active Pending
- 2021-02-12 EP EP21754343.8A patent/EP4103186A4/en not_active Withdrawn
- 2021-02-12 US US17/799,641 patent/US20230130766A1/en active Pending
- 2021-02-12 WO PCT/US2021/018044 patent/WO2021163633A1/en not_active Ceased
- 2021-02-12 JP JP2022549152A patent/JP2023513797A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5579715B2 (ja) | ｃｄｋ阻害剤および抗悪性腫瘍剤を含む治療用組合せ | |
| US8642602B2 (en) | Method of inhibiting fibrogenesis and treating fibrotic disease | |
| CA2927980C (en) | Tyrosine derivatives and compositions comprising them | |
| JP2022145800A (ja) | 静止細胞標的化およびｅｇｆｒ阻害剤を用いた新生物の処置のための組み合わせ | |
| CN108024541A (zh) | 用于治疗癌症的方法 | |
| CN109328187A (zh) | 一种具有fgfr抑制活性的新型化合物及其制备和应用 | |
| JP2013512903A5 (enExample) | ||
| RU2007116119A (ru) | Производные циклоспорина, замещенные 3-эфиром и 3-тиоэфиром, для лечения и профилактики инфекционного гепатита с | |
| JP2018052974A (ja) | チロシンキナーゼ阻害剤との組合せ製品及びそれらの使用 | |
| JP2006503850A5 (enExample) | ||
| EP4322942A1 (en) | Combination comprising everolimus and amcenestrant | |
| JP2014513705A (ja) | 進行性固形腫瘍の治療方法 | |
| RU2011150619A (ru) | Комбинация ингибитора фосфоинозитид-3-киназы и противодиабетического соединения | |
| JP2023544716A5 (enExample) | ||
| JP2013511526A5 (enExample) | ||
| JP2011518168A5 (enExample) | ||
| US20150087886A1 (en) | Novel bifunctional metnase/intnase inhibitors and related compositions and methods of treatment of cancer | |
| WO2008124823A1 (en) | Method of treating melanoma | |
| JP2022519764A5 (enExample) | ||
| JP2018522049A5 (enExample) | ||
| JPWO2022014640A5 (enExample) | ||
| JP2013523867A5 (enExample) | ||
| JP2023509191A (ja) | 癌を治療するための組み合わせ療法 | |
| JP2025502240A5 (enExample) | ||
| CN113509475A (zh) | Bcl-2/bcl-xl抑制剂的组合及相关用途 |